ESC 2026: Aficamten breaks new ground in nonobstructive HCM

ConferencepositiveAficamtenPositive

AI Analysis

Summary

Aficamten demonstrated improvements in cardiac structure and diastolic function at ESC 2026, strengthening its therapeutic potential for nonobstructive hypertrophic cardiomyopathy.

Outcome Details

Aficamten demonstrated improvements in cardiac structure and diastolic function in nonobstructive HCM

Importance:6/10

Sentiment:

0.70

cardiologyheart diseaseHCMESC 2026clinical data

Related Companies

$STTK

Read the original article

Published by Pharmaceutical Technology on August 31, 2026 1:40 PM

Read Original